Famitinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Famitinib
Accession Number
DB11741
Description

Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 410.493
Monoisotopic: 410.211804288
Chemical Formula
C23H27FN4O2
Synonyms
Not Available
External IDs
  • SHR1020

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrrolopyridines. These are compounds containing a pyrrolopyridine moiety, which consists of a pyrrole ring fused to a pyridine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolopyridines
Sub Class
Not Available
Direct Parent
Pyrrolopyridines
Alternative Parents
Indolines / Aryl fluorides / Substituted pyrroles / Benzenoids / Pyridines and derivatives / Vinylogous amides / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids and derivatives / Trialkylamines
show 7 more
Substituents
Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
768FW21J3L
CAS number
1044040-56-3
InChI Key
GKEYKDOLBLYGRB-LGMDPLHJSA-N
InChI
InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-
IUPAC Name
(3Z)-3-({5-[2-(diethylamino)ethyl]-3-methyl-4-oxo-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-2-yl}methylidene)-5-fluoro-2,3-dihydro-1H-indol-2-one
SMILES
CCN(CC)CCN1CCC2=C(C(C)=C(N2)\C=C2/C(=O)NC3=CC=C(F)C=C23)C1=O

References

General References
Not Available
PubChem Compound
16662431
PubChem Substance
347828099
ChemSpider
17595500
BindingDB
50331023
ChEMBL
CHEMBL1278146

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentMetastatic Colorectal Cancer (MCRC) / Recurrent Colorectal Cancer1
3Not Yet RecruitingTreatmentGastrointestinal Stromal Tumors1
3TerminatedTreatmentNon Squamous Non Small Cell Lung1
2Active Not RecruitingTreatmentGastrointestinal Stromal Tumors1
2CompletedTreatmentColorectal Cancers / Metastatic Colorectal Cancer (MCRC) / Recurrent Colorectal Cancer1
2CompletedTreatmentMetastatic Nasopharyngeal Carcinoma / Recurrent Nasopharyngeal Carcinoma1
2CompletedTreatmentMetastatic Renal Cell Cancer / Renal Cell Adenocarcinoma1
2Not Yet RecruitingTreatmentEGFR-mutant Non-small Cell Lung Cancer1
2Not Yet RecruitingTreatmentIntrahepatic Cholangiocarcinoma1
2Not Yet RecruitingTreatmentNeoplasms, Breast1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0708 mg/mLALOGPS
logP3.44ALOGPS
logP2.68ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)11.46ChemAxon
pKa (Strongest Basic)9.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area68.44 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity119.31 m3·mol-1ChemAxon
Polarizability46.14 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 14:43 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates